A novel bacteriophage having specific killing activity against Clostridium perfringens and an antibacterial composition containing the same

The bacteriophage CJ_CP_20-25 addresses the shortage of effective bacteriophages by providing a broad-spectrum, acid and heat-resistant solution to treat Clostridium perfringens infections, ensuring effective prevention and treatment of diseases in livestock.

JP7580624B2Active Publication Date: 2024-11-11CJ CHEILJEDANG CORP
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2023552166
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2021-02-25
Filing Date
2021-06-15
Publication Date
2024-11-11
Estimated Expiration
2041-06-15

AI Technical Summary

Technical Problem

There is a shortage of bacteriophages with broad lytic spectrum and acid and heat resistance to effectively prevent and treat infectious diseases caused by Clostridium perfringens, which are prevalent in the livestock industry, particularly affecting young animals and leading to severe health issues like necrotizing enterocolitis.

Method used

Development of a bacteriophage CJ_CP_20-25, specifically deposited under accession number KCCM12934P, which has the ability to target and kill Clostridium perfringens, and is formulated into various compositions for administration as a feed additive, drinking water additive, disinfectant, or therapeutic agent, ensuring high specificity and stability.

Benefits of technology

The bacteriophage CJ_CP_20-25 effectively prevents and treats Clostridium perfringens infections by killing the bacteria, reducing the risk of transmission and alleviating symptoms, while maintaining activity across a wide pH range and high temperatures, thus offering a viable alternative to antibiotics.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007580624000003
    Figure 0007580624000003
  • Figure 0007580624000004
    Figure 0007580624000004
  • Figure 0007580624000005
    Figure 0007580624000005
Patent Text Reader

Abstract

The present application relates to a novel bacteriophage having specific killing ability against Clostridium perfringens and an antibacterial composition containing the same. The novel bacteriophage CJ_CP_20-25 has the effect of specifically killing Clostridium perfringens and has excellent acid resistance and heat resistance, and therefore can be widely used in antibiotics, feed additives, drinking water additives, feed, drinking water, disinfectants, cleaning agents, etc. for the prevention or treatment of infectious diseases caused by Clostridium perfringens.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present application relates to a novel bacteriophage having specific killing activity against Clostridium perfringens and an antibacterial composition containing the same. [Background technology]

[0002] Clostridium perfringens is a large, gram-positive, obligately anaerobic bacillus that is non-flagellated and known to form spores. Clostridium perfringens is a bacterium that induces diarrhea in animals, particularly livestock such as chickens and pigs, and is recognized as one of the important and fatal pathogens in the livestock industry, comparable to poultry typhoid caused by Salmonella.

[0003] Necrotic enteritis caused by Clostridium perfringens infection, which is one of the most frequent diseases in the poultry and swine industry, induces severe necrotic lesions in the lower part of the small intestine of chickens and pigs, and induces bloody diarrhea as the main symptom. Depending on the severity of the disease, necrotic enteritis causes dehydration and intermittent diarrhea in infected animals, gradually weakening the animal's body and inducing growth retardation, making it a major problem in the livestock industry. Furthermore, since Clostridium perfringens, which causes necrotic enteritis, is easily transmitted through animal feces, it can easily be transmitted between animals in a communal farm by oral infection through soil or contaminated feed, and the high incidence rate of the disease is particularly problematic in young animals.

[0004] In the livestock industry, various antibiotics have been used to prevent and treat diseases caused by bacterial infections in livestock. However, problems such as misuse, overuse, and resistance of antibiotics, as well as the possibility of antibiotics remaining in the animal's body, have come to the surface, and there are now many restrictions on the administration of antibiotics worldwide.

[0005] Recently, bacteriophages, which are bacteria-specific viruses that infect specific bacteria and suppress their growth, have been studied as new alternatives to antibiotics because they have stronger host specificity than antibiotics, but there is still an absolute shortage of them. Therefore, in order to prevent and treat infectious diseases caused by Clostridium perfringens, which is a major problem in the livestock industry, including pig and chicken farming, there is a continuous demand for the development of new bacteriophages that have a wide range of lytic spectra, excellent acid resistance and heat resistance, and high industrial applicability. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] U.S. Patent No. 6,942,858 Summary of the Invention [Problem to be solved by the invention]

[0007] The present application aims to provide bacteriophage CJ_CP_20-25, deposited under accession number KCCM12934P, which has a specific killing activity against Clostridium perfringens, a composition for preventing or treating an infectious disease caused by Clostridium perfringens, which contains the bacteriophage CJ_CP_20-25 as an active ingredient, an antibiotic, a feed additive, a drinking water additive, a disinfectant or cleaning agent, a feed containing the feed additive, or a drinking water containing the drinking water additive.

[0008] In addition, the present application aims to provide a method for preventing or treating an infectious disease caused by Clostridium perfringens using the bacteriophage CJ_CP_20-25 or a composition for preventing or treating an infectious disease caused by Clostridium perfringens containing the same as an active ingredient.

[0009] Furthermore, the present application aims to provide use of the bacteriophage CJ_CP_20-25, or a composition for preventing or treating an infectious disease caused by Clostridium perfringens containing it as an active ingredient, for the manufacture of an agent for preventing or treating an infectious disease caused by Clostridium perfringens. [Means for solving the problem]

[0010] Each description and embodiment disclosed in this application applies to each of the other descriptions and embodiments. That is, any combination of the various elements disclosed in this application is included in this application. In addition, this application is not limited to the specific description below. Moreover, those skilled in the art will recognize and be able to ascertain, using no more than routine experimentation, many equivalents to the specific aspects of this application described in this application. Moreover, the equivalents are intended to be included in this application.

[0011] One aspect provides a bacteriophage CJ_CP_20-25 having specific killing activity against Clostridium perfringens and deposited under Accession No. KCCM12934P.

[0012] In this specification, "Clostridium perfringens (CP)" is a gram-positive anaerobic bacillus, which is a causative bacterium that induces infectious diseases in animals such as chickens and pigs.

[0013] As used herein, the term "bacteriophage" refers to a bacteria-specific virus that infects a specific bacterium and inhibits the growth of that bacterium, and that contains single-stranded or double-stranded DNA or RNA as genetic material.

[0014] Another aspect provides a composition for preventing or treating an infectious disease caused by Clostridium perfringens, comprising the bacteriophage CJ_CP_20-25 as an active ingredient.

[0015] The bacteriophage CJ_CP_20-25 is as described above.

[0016] Since the bacteriophage CJ_CP_20-25 has a specific killing ability against Clostridium perfringens, when it is administered to an individual before the onset of an infectious disease caused by Clostridium perfringens, it can kill Clostridium perfringens that flows into the individual, thereby suppressing infection caused by Clostridium perfringens and preventing an infectious disease caused by Clostridium perfringens. Furthermore, when the bacteriophage CJ_CP_20-25 is administered to an individual who has developed an infectious disease caused by Clostridium perfringens, it can kill Clostridium perfringens present in the individual, thereby alleviating or eliminating the symptoms caused by the disease, and thus it is possible to treat the infectious disease caused by Clostridium perfringens.

[0017] As used herein, "prevention" refers to any action that inhibits or delays the onset of disease in an individual by administering a bacteriophage or composition, and "treatment" refers to any action that improves, alleviates, or eliminates symptoms of disease in an individual by administering a bacteriophage or composition.

[0018] The infectious disease caused by Clostridium perfringens is, for example, necrotizing enteritis, but is not limited thereto.

[0019] In this specification, "necrotic enteritis" refers to one of the infectious diseases induced by Clostridium perfringens, and corresponds to a bacterial disease that frequently occurs in livestock such as chickens and causes a lot of damage. The symptoms of necrotic enteritis appear due to excessive proliferation of Clostridium perfringens in the small intestine, inducing necrosis of the digestive mucosa and sudden diarrhea. For example, in farmed pigs, in the case of peracute necrotic enteritis, the pig dies 1 to 2 days after the onset, and in the case of acute necrotic enteritis, the pig dies 2 to 3 days after diarrhea mixed with blood. In addition, in the case of subacute necrotic enteritis, diarrhea (without bloody stool) continues for 5 to 7 days, causing weakness and dehydration, and in the case of chronic necrotic enteritis, intermittent diarrhea is induced, causing growth retardation.

[0020] The composition for preventing or treating an infectious disease caused by Clostridium perfringens contains the bacteriophage CJ_CP_20-25 at 1×10 2 ~1×10 12 PFU / mL or 1×10 5 ~1×10 10 It may be contained in terms of PFU / g.

[0021] The composition for preventing or treating an infectious disease caused by Clostridium perfringens may further contain a pharma- ceutically acceptable carrier, and may be formulated together with the carrier and provided as a food, pharmaceutical, feed additive, drinking water additive, etc.

[0022] As used herein, the term "pharmaceutical acceptable carrier" refers to a carrier, diluent, etc. that does not stimulate living organisms and does not impair the biological activity and properties of the administered compound.

[0023] The type of carrier contained in the composition is not particularly limited, and any pharma- ceutically acceptable carrier that is commonly used in the art can be used. Examples of the carrier include, but are not limited to, saline, sterile water, Ringer's solution, buffered saline, albumin injection, glucose solution, maltodextrin solution, glycerin, etc. These may be used alone or in combination of two or more, and other common additives such as antioxidants, buffers, bacteriostatic agents, etc. may be added as necessary. In addition, diluents, dispersants, binders, and lubricants may be further added to the composition to form an injectable dosage form such as an aqueous solution, suspension, or emulsion, or a pill, capsule, granule, or tablet.

[0024] The composition for preventing or treating infectious diseases caused by Clostridium perfringens may be administered orally or parenterally, or may be applied or sprayed to the diseased site. In the case of parenteral administration, intravenous, intraperitoneal, intramuscular, subcutaneous or local administration may be used. The suitable application, spray and dosage of the composition vary depending on factors such as the formulation method, administration method, age, weight, sex, degree of disease symptoms, diet, administration time, administration route, excretion rate, reaction sensitivity of the target animal and patient, and usually an effective dosage for the intended treatment can be easily determined and prescribed by a skilled physician or veterinarian.

[0025] The oral dosage form of the composition for preventing or treating infectious diseases caused by Clostridium perfringens may be, for example, a tablet, a troche, a lozenge, an aqueous or oily suspension, a prepared powder or granule, an emulsion, a hard or soft capsule, a syrup or an elixir. To be formulated into a dosage form such as a tablet or a capsule, a binder such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose, gelatin, an excipient such as dibasic calcium phosphate, a disintegrant such as corn starch or sweet potato starch, a lubricant such as magnesium stearate, calcium stearate, sodium stearyl fumarate, or polyethylene glycol wax may be included, and in the case of a capsule dosage form, a liquid carrier such as a fatty oil may be further included in addition to the above-mentioned substances.

[0026] The parenteral dosage form of the composition for preventing or treating infectious diseases caused by Clostridium perfringens includes injection forms such as subcutaneous injection, intravenous injection, and intramuscular injection, suppository forms, and spray forms such as aerosols that can be inhaled through the respiratory tract. To prepare an injection form, the composition of the present invention may be mixed with water together with a stabilizer or buffer to form a solution or suspension, which may be formulated for unit administration in an ampoule or vial. In the case of a spray form such as an aerosol, a propellant for spraying a water-dispersed concentrate or wet powder may be mixed with an additive.

[0027] The composition for preventing or treating an infectious disease caused by Clostridium perfringens may contain a preservative, a stabilizer, a wetting agent or an emulsifier, a cryoprotectant, an excipient, and the like.

[0028] The preservatives, stabilizers, or excipients may be included in the composition in an effective amount sufficient to reduce deterioration of the composition.

[0029] In this specification, "deterioration in quality" may include a decrease in the number of bacteria, a decrease in activity, or a combination thereof, of bacteriophage CJ_CP_20-25 contained in a composition or the like.

[0030] For example, the composition may include an effective amount of a preservative, stabilizer or excipient sufficient to reduce deterioration of the composition, thereby allowing bacteriophage CJ_CP_20-25 to survive or remain active for a longer period in the composition compared to bacteriophage present in nature.

[0031] The preservative, stabilizer or excipient may be any commonly used in the art, as long as it can reduce deterioration of the composition. For example, the stabilizer may be one or more selected from the group consisting of alginate, sodium alginate, casein, sodium caseinate, cellulose, methylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, pectin, gelatin, gum arabic, xanthan gum, dextran, cyclodextrin and starch.

[0032] The cryoprotectant may be present in the composition in an effective amount sufficient to reduce degradation of the composition when the composition is in a freeze-dried state, e.g., unlike naturally occurring bacteriophages that are less active or non-viable in a freeze-dried composition, the cryoprotectant may be present in an effective amount sufficient to reduce degradation of the composition when the composition is in a freeze-dried state, such that bacteriophage activity is maintained or bacteriophage survive in the freeze-dried composition.

[0033] The cryoprotectant may be any agent commonly used in the art, so long as it is capable of reducing the deterioration of the composition in a freeze-dried state. For example, the cryoprotectant may be one or more selected from the group consisting of glycerin, ethylene glycol, propylene glycol, dimethyl sulfoxide (DMSO), glucose, trehalose, maltodextrin, dextrin, skim milk, and starch.

[0034] Yet another aspect provides an antibiotic comprising the bacteriophage CJ_CP_20-25 as an active ingredient.

[0035] The bacteriophage CJ_CP_20-25 is as described above.

[0036] The term "antibiotic" as used herein means a preparation that kills bacteria or inhibits the growth of bacteria, and is a general term for antiseptics, disinfectants, and antibacterial agents.

[0037] The antibiotic containing the bacteriophage CJ_CP_20-25 as an active ingredient has a very high specificity against Clostridium perfringens compared to conventional antibiotics, and can kill only specific pathogenic bacteria without killing beneficial bacteria. It also does not induce drug resistance, so it has the effect of extending the product lifespan compared to conventional antibiotics.

[0038] The antibiotics can be produced by production methods commonly used in the art.

[0039] The antibiotic may contain an effective amount of an additive sufficient to reduce deterioration of the antibiotic, and the additive may be a preservative, stabilizer, excipient, cryoprotectant, etc. The antibiotic may contain the additive, so that the bacteriophage CJ_CP_20-25 survives for a longer period of time or maintains its activity in the antibiotic, unlike a bacteriophage present in a natural state. The preservative, stabilizer, excipient, or cryoprotectant may be any preservative commonly used in the art, as long as it can reduce deterioration of the antibiotic.

[0040] Yet another aspect provides a feed additive comprising the bacteriophage CJ_CP_20-25 as an active ingredient. Yet another aspect provides a feed comprising the feed additive. Yet another aspect provides a drinking water additive comprising the bacteriophage CJ_CP_20-25 as an active ingredient. Yet another aspect provides drinking water comprising the drinking water additive.

[0041] The bacteriophage CJ_CP_20-25 is as described above.

[0042] The feed additive or drinking water additive may be prepared in the form of a composition containing bacteriophage CJ_CP_20-25 and mixed with feed or drinking water, or may be used by directly adding the bacteriophage CJ_CP_20-25 during the production of feed or drinking water.

[0043] The bacteriophage CJ_CP_20-25 contained in the feed additive or drinking water additive may be in a liquid state or a dried solid state, specifically in a dried powder form. The drying method of the bacteriophage CJ_CP_20-25 includes, but is not limited to, ventilation drying, natural drying, spray drying, or freeze drying. The bacteriophage CJ_CP_20-25 may be mixed in a dried powder form at 0.05 to 10% by weight, specifically 0.1 to 2% by weight, of the weight of the feed additive or drinking water additive.

[0044] The feed additive or drinking water additive containing the bacteriophage CJ_CP_20-25 as an active ingredient may further contain other additives as necessary. Examples of the additives that can be used include, for example, binders, emulsifiers, preservatives, etc., which are added to prevent deterioration of the quality of the feed or drinking water, and amino acid preparations, vitamin preparations, enzyme preparations, live bacteria preparations, flavoring agents, non-protein nitrogen compounds (NPN), silicate preparations, buffers, colorants, extractants, oligosaccharides, etc., which are added to increase the utility of the feed or drinking water, but are not limited thereto. These may be added alone or in combination of two or more kinds.

[0045] The raw materials other than the bacteriophage CJ_CP_20-25 contained in the feed or drinking water may be any materials commonly used in the art. Examples of the feed include plant feed such as grains, roots and fruits, food processing by-products, algae, fiber, pharmaceutical by-products, oils and fats, starches, melons, and grain by-products, and animal feed such as proteins, inorganic substances, oils and fats, minerals, single-cell proteins, zooplankton, and food and drink, but are not limited thereto. These may be used alone or in combination of two or more.

[0046] The feed additive may be contained in an amount of 0.05 to 10 parts by weight, for example, 0.1 to 2 parts by weight, relative to 100 parts by weight of feed, and the drinking water additive may be contained in an amount of 0.0001 to 0.01 part by weight, for example, 0.001 to 0.005 part by weight, relative to 100 parts by weight of drinking water.

[0047] The feed additive, feed, drinking water additive or drinking water can be produced by a production method commonly used in the art.

[0048] The feed additive, feed, drinking water additive, or drinking water may contain an effective amount of an additive sufficient to reduce deterioration of the quality thereof, and the additive may be a preservative, stabilizer, excipient, cryoprotectant, or the like. The feed additive, feed, drinking water additive, or drinking water may contain the additive, so that bacteriophage CJ_CP_20-25 survives for a longer period of time or maintains its activity in the feed additive, feed, drinking water additive, or drinking water, unlike bacteriophages present in a natural state. The preservative, stabilizer, excipient, or cryoprotectant may be any preservative commonly used in the art, as long as it can reduce deterioration of the quality of the feed additive, feed, drinking water additive, or drinking water.

[0049] Yet another embodiment provides a disinfectant comprising the bacteriophage CJ_CP_20-25 as an active ingredient. Yet another embodiment provides a cleaning agent comprising the bacteriophage CJ_CP_20-25 as an active ingredient.

[0050] The bacteriophage CJ_CP_20-25 is as described above.

[0051] The formulation of the disinfectant or cleaner is not particularly limited and may be prepared in a formulation commonly known in the art. The disinfectant or cleaner may be prepared by a manufacturing method commonly used in the art.

[0052] The disinfectant is applied to eliminate Clostridium perfringens and may be applied to, but is not limited to, animal activity areas, slaughterhouses, killing areas, food preparation areas, and food preparation equipment.

[0053] The cleaning agent is used for, but is not limited to, cleaning the skin surfaces, body parts, etc. of animals that have been exposed to or are at risk of being exposed to Clostridium perfringens.

[0054] The disinfectant or cleaning agent may contain an additive in an effective amount sufficient to reduce the deterioration of the quality of the disinfectant or cleaning agent, and the additive may be a preservative, stabilizer, excipient, cryoprotectant, etc. The disinfectant or cleaning agent may contain the additive so that the bacteriophage CJ_CP_20-25 survives for a longer period of time or retains its activity in the disinfectant or cleaning agent, unlike the bacteriophage present in the natural state. The preservative, stabilizer, excipient, or cryoprotectant may be any preservative commonly used in the art, as long as it can reduce the deterioration of the disinfectant or cleaning agent.

[0055] Yet another aspect provides a method for preventing or treating an infectious disease caused by Clostridium perfringens, comprising the step of administering to an animal other than a human a composition for preventing or treating an infectious disease caused by Clostridium perfringens, the composition comprising the bacteriophage CJ_CP_20-25 or an active ingredient thereof.

[0056] The bacteriophage CJ_CP_20-25, the composition for preventing or treating an infectious disease caused by Clostridium perfringens containing the bacteriophage CJ_CP_20-25 as an active ingredient, and the infectious disease caused by Clostridium perfringens are as described above. Specifically, the infectious disease caused by Clostridium perfringens is, for example, necrotizing enteritis.

[0057] The preventive or therapeutic method specifically includes a step of administering a pharma- tically effective amount of the bacteriophage CJ_CP_20-25 or a composition containing it as an active ingredient to a non-human animal infected or at risk of being infected by Clostridium perfringens. The bacteriophage CJ_CP_20-25 or a composition containing it as an active ingredient may be administered to the animal in the form of a pharmaceutical preparation, or may be administered in the form of a feed additive or drinking water additive by mixing it with the animal's feed or drinking water and allowing the animal to ingest it.

[0058] The administration route of the bacteriophage CJ_CP_20-25 or a composition containing it as an active ingredient can be various oral or parenteral routes as long as it can deliver it to the target tissue. Specifically, it can be administered by conventional methods such as oral, rectal, topical, intravenous, intraperitoneal, intramuscular, intraarterial, transdermal, intranasal, and inhalation.

[0059] The appropriate total daily usage amount of the bacteriophage CJ_CP_20-25 or a composition containing it as an active ingredient will be determined by the attending physician within the scope of sound medical judgment, as will be apparent to one of ordinary skill in the art.

[0060] The specific pharmacologic effective amount of the bacteriophage CJ_CP_20-25 or a composition containing it as an active ingredient for a particular animal is determined taking into consideration the type and degree of the response to be achieved, the age, weight, general health condition, sex, and diet of the individual, as well as the administration time, administration route, secretion rate of the composition, and treatment period of the bacteriophage CJ_CP_20-25 or a composition containing it as an active ingredient, and varies depending on various factors including drugs used simultaneously or at different times, other components of the composition, and similar factors well known in the pharmaceutical field.

[0061] The non-human animal is not particularly limited as long as it is an animal that can be infected by Clostridium perfringens. For example, the non-human animal is a bird or a mammal, specifically including, but not limited to, chickens, ducks, pigs, etc.

[0062] Yet another aspect provides use of the bacteriophage CJ_CP_20-25, or a composition for preventing or treating an infectious disease caused by Clostridium perfringens containing it as an active ingredient, for the manufacture of an agent for preventing or treating an infectious disease caused by Clostridium perfringens.

[0063] The bacteriophage CJ_CP_20-25, the composition for preventing or treating an infectious disease caused by Clostridium perfringens containing the bacteriophage CJ_CP_20-25 as an active ingredient, and the infectious disease caused by Clostridium perfringens are as described above. Specifically, the infectious disease caused by Clostridium perfringens is, for example, necrotizing enteritis. Effect of the Invention

[0064] The novel bacteriophage CJ_CP_20-25 has the effect of specifically killing Clostridium perfringens and has excellent acid and heat resistance, so it can be widely used in antibiotics, feed additives, drinking water additives, feed, drinking water, disinfectants, cleaning agents, etc. for the prevention or treatment of infectious diseases caused by Clostridium perfringens. [Brief description of the drawings]

[0065] [Figure 1] This is an electron microscope image of the novel bacteriophage CJ_CP_20-25. [Diagram 2] 1 is a graph showing the results of confirming the pH stability of the novel bacteriophage CJ_CP_20-25. [Diagram 3] 1 is a graph showing the results of confirming the stability of novel bacteriophage CJ_CP_20-25 at 60° C. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0066] The present invention will be described in detail below with reference to examples. However, these examples are merely illustrative of the present invention and are not intended to limit the present invention. EXAMPLES

[0067] Isolation of bacteriophages capable of killing Clostridium perfringens (CP) Example 1-1. Preparation of fecal sample pretreatment solution Fecal samples from pigs, chickens, and cattle were collected from farms in Seoul, Gyeonggi, Chungcheong, and Gyeongsang provinces in Korea. 20 g of each sample was diluted in 80 mL of PBS and centrifuged at 10,000 rpm for 15 min. The supernatant was filtered through a 0.2 μm filter, and then 10% (w / v) sodium chloride aqueous solution was added to the filtrate and stored at 4°C for 12 h. Then, 10% (w / v) polyethylene glycol 8000 (Sigma-Aldrich, Cat. No. P2139) was added to it and stored at 4°C for 12 h, and then centrifuged at 15,000 rpm for 1 h for concentration to remove the supernatant. The precipitate was dissolved in 10 mL of SM buffer (5.8 g / L sodium chloride, 2 g / L MgSO4·7H2O, 0.05 M Tris-Cl (pH 7.5)), then filtered through a 0.2 μm filter, and the filtrate was stored at 4°C.

[0068] Example 1-2. Preparation of bacteriophage concentrate CP strains isolated from fecal samples collected from livestock farms in Seoul, Gyeonggi, Chungcheong, and Gyeongsang regions of Korea, and CP strains provided by the National Veterinary Medical and Quarantine Service were inoculated into 2 mL of BHI (Brain Heart Infusion) medium and cultured at 42°C under anaerobic conditions for 18 hours. Then, 1 mL of the culture solution of the CP strain and 1 mL of the fecal sample pretreatment solution obtained in Example 1-1 were inoculated into 50 mL of BHI medium and cultured at 42°C for 18 hours. The mixed culture solution was centrifuged at 6,000 rpm for 20 minutes, and the supernatant was filtered through a 0.2 μm filter, to which 10% (w / v) polyethylene glycol 8000 was added and stored at 4°C for 12 hours. Then, the mixture was centrifuged at 15,000 rpm for 1 hour to concentrate, the supernatant was removed, and the precipitate was dissolved in 1 mL of SM buffer, filtered through a 0.2 μm filter, and the filtrate was stored at 4°C.

[0069] Example 1-3. Screening and isolation of bacteriophages 50 μL of the bacteriophage concentrate prepared in Example 1-2 was mixed with 5 mL of 0.7% (w / v) agar (BD DIFCO, Cat. No. 44164) and 50 μL of a culture medium obtained by shaking culture of the same CP strain used in Example 1-2 to an optical density (OD) of 2 at 600 nm, and a double-layer agar plaque assay was performed using a 150 mm diameter BHI plate medium. The plaques formed on the soft agar were punched with a 200 μL tip and eluted by placing them in 0.5 mL of SM buffer. The eluted bacteriophage-containing solution was subjected to the double-layer agar plaque assay repeatedly until a single plaque of the same shape was formed, and a pure bacteriophage-containing solution was isolated. The obtained bacteriophage-containing solution was filtered through a 0.2 μm filter, 10% (w / v) polyethylene glycol 8000 was added thereto, and the mixture was stored at 4° C. for 12 hours. Then, for concentration, the mixture was centrifuged at 15,000 rpm for 1 hour to remove the supernatant, and the precipitate was dissolved in 1 mL of SM buffer and filtered through a 0.2 μm filter, and the filtrate was stored at 4°C. EXAMPLES

[0070] Whole genome sequencing (WGS) analysis of isolated bacteriophages DNA was extracted from 1 mL of the bacteriophage concentrate isolated in Examples 1-3 using the CsCl gradient method and a phage DNA isolation kit (Norgen Biotek-Corp. Kit, Cat. No. 46800). Whole genome sequencing analysis was performed by Macrogen Inc., and genes were assembled using de novo assembly software (SPAdes 3.13.0), and open reading frames (ORFs) were generated using GeneMark.hmm and NCBI ORF finder. The functions of each ORF were annotated using the BLASTP (E values ​​of <0.1) and PSI-BLAST (E value of <0.005) programs.

[0071] As a result, the isolated bacteriophage was confirmed to have the base sequence of SEQ ID NO: 1, which is 51,670 bp, 73 ORFs, and has a G+C content of 34.10%, which shows 97% sequence identity with the previously reported Clostridium phage CP3 (MF001357.1), but it was confirmed that there was no bacteriophage with 100% identical fragments, and therefore the bacteriophage was found to be a newly isolated bacteriophage. Therefore, the novel bacteriophage was named bacteriophage CJ_CP_20-25 and deposited with the Korean Culture Center of Microorganisms, an international depository institution under the Budapest Treaty, on January 18, 2021 under the accession number KCCM12934P. EXAMPLES

[0072] Morphological analysis of bacteriophage CJ_CP_20-25 In order to obtain a high-purity bacteriophage solution, the CsCl gradient method was performed. Specifically, a CsCl solution was prepared by dissolving it in SM buffer with a density of 1.7, 1.5, 1.45, or 1.3, and 2 mL of the CsCl solution was dispensed into a 15 mL ultracentrifuge tube (Beckman Coulter, Cat. No. Z00901SCA) so as to form layers from high density to low density, and 2 mL of the bacteriophage CJ_CP_20-25 concentrate obtained in Example 1-3 was dispensed into the top layer. This was centrifuged at 4°C and 25,000 rpm for 2 hours, and then only the white bacteriophage layer formed in the tube was collected with a syringe (Satorius, Cat. No. 17822-K). One microliter of the collected bacteriophage solution was spotted onto a carbon-coated copper grid, which was then stained with 2% uranyl acetate for 15 seconds, and the morphology was observed under an electron microscope (TEM, JEOL JEM-101, Tokyo, Japan).

[0073] As a result, as shown in Figure 1, bacteriophage CJ_CP_20-25 was observed to have a morphologically icosahedral head and a contractile tail approximately 100 nm in length, and was found to belong to the Caudovirales order and Myoviridae family. EXAMPLES

[0074] Evaluation of pH stability of bacteriophage CJ_CP_20-25 To confirm whether bacteriophage CJ_CP_20-25 has stability over a wide pH range, solutions of pH 4, 7, 7.5, and 10 (pH 4: 0.2 M sodium acetate solution; pH 7, 7.5: 0.2 M sodium phosphate solution; pH 10: 0.2 M Tris-HCl solution) were prepared. 450 μL of each pH solution and 2 × 10 10 50 μL of PFU / mL bacteriophage solution was mixed and allowed to stand at 4° C. for 2 hours, after which a double-layer agar plaque assay was performed to evaluate the increase or decrease in titer.

[0075] As a result, as shown in Figure 2, bacteriophage CJ_CP_20-25 was stable and did not lose activity at pH 7 to 10, and even at pH 4, its activity decreased by only about 1.3 logs compared to the pH 7.5 group, indicating that it is a bacteriophage with excellent acid resistance. EXAMPLES

[0076] Evaluation of the thermal stability of bacteriophage CJ_CP_20-25 To confirm whether bacteriophage CJ_CP_20-25 has stability at high temperatures, 2 × 10 8 500 μL of the PFU / mL bacteriophage solution was left to stand at 60° C. for 0, 3, 6 or 24 hours, and then a double-layer agar plaque assay was performed to evaluate the increase or decrease in titer.

[0077] As a result, as shown in Figure 3, when exposed to 60°C for 3 hours, bacteriophage CJ_CP_20-25 showed an activity decrease of about 1.2 logs compared to the control group exposed for 0 hours, when exposed for 6 hours, it showed an activity decrease of about 1.6 logs compared to the control group, and when exposed for 24 hours, it showed an activity decrease of about 5.4 logs compared to the control group, but still had activity. Therefore, it was found that bacteriophage CJ_CP_20-25 is a bacteriophage with excellent heat resistance. EXAMPLES

[0078] Evaluation of the lytic spectrum of bacteriophage CJ_CP_20-25 In order to evaluate the bacteriophage CJ_CP_20-25 lysis range, CP strains isolated from fecal samples collected from livestock farms in Seoul, Gyeonggi, Chungcheong, and Gyeongsang regions of Korea, and 45 CP strains provided by the National Veterinary Medical and Quarantine Service were cultured in BHI liquid medium, and then 50 μL of each of the cultures of the strains was inoculated into 5 mL of 0.7% soft agar, poured into a Petri dish for plating, and then left to stand for 5 minutes. Then, 10 μL of the bacteriophage CJ_CP_20-25 concentrate obtained in Example 1-3 was spotted on the soft agar, and then left to stand at 42° C. for 18 hours. After the end of the culture, the bacteriophage CJ_CP_20-25 lysis range was evaluated based on the presence or absence of lysis plaques formed on the soft agar.

[0079] [Table 1]

[0080] As a result, as shown in Table 1, lytic plaques were formed in all of the 45 CP strains tested, confirming that bacteriophage CJ_CP_20-25 has the ability to kill a wide range of CP strains.

[0081] From the above description, a person having ordinary knowledge in the technical field to which the present application pertains will understand that the present application can be implemented in other specific forms without changing its technical idea or essential features. It should be understood that the above examples are merely illustrative and not limiting. The present application should be interpreted as including all modifications and variations derived from the meaning and scope of the claims and their equivalent concepts, rather than the specification.

[0082] TIFF0007580624000002.tif224170

Claims

1. Bacteriophage CJ_CP_20-25, which has a specific killing activity against Clostridium perfringens (CP) and has the nucleotide sequence of SEQ ID NO:1, has been deposited under accession number KCCM12934P.

2. A composition for preventing or treating an infectious disease caused by Clostridium perfringens, comprising the bacteriophage CJ_CP_20-25 according to claim 1 as an active ingredient.

3. The composition according to claim 2, wherein the infectious disease caused by Clostridium perfringens is necrotizing enterocolitis.

4. An antibiotic comprising the bacteriophage CJ_CP_20-25 of claim 1 as an active ingredient.

5. A feed additive comprising the bacteriophage CJ_CP_20-25 according to claim 1 as an active ingredient.

6. A feed comprising the feed additive according to claim 5.

7. A drinking water additive comprising the bacteriophage CJ_CP_20-25 of claim 1 as an active ingredient.

8. 8. Drinking water comprising the drinking water additive of claim 7.

9. A disinfectant comprising the bacteriophage CJ_CP_20-25 of claim 1 as an active ingredient.

10. A cleaning agent comprising the bacteriophage CJ_CP_20-25 according to claim 1 as an active ingredient.

11. A method for preventing or treating an infectious disease caused by Clostridium perfringens, comprising the step of administering the bacteriophage CJ_CP_20-25 according to claim 1 or the composition according to claim 2 to an animal other than a human.

12. The method of claim 11, wherein the infectious disease caused by Clostridium perfringens is necrotizing enterocolitis.

13. Use of a composition comprising the bacteriophage CJ_CP_20-25 according to claim 1 as an active ingredient in an animal other than a human, for preventing or treating an infectious disease caused by Clostridium perfringens.

14. Use of the bacteriophage CJ_CP_20-25 according to claim 1 in the manufacture of a composition for preventing or treating an infectious disease caused by Clostridium perfringens.

Citation Information

Patent Citations

  • Novel clostridium perfringens bacteriophage clo-PEP-1 and use thereof for inhibiting proliferation of clostridium perfringens

    US20170340685A1

  • Compositions containing bacteriophages and methods of using bacteriophages to treat infections

    US6942858B1